Altre lingue Abliva AB

Azioni

ABLI

SE0002575340

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 18:00:00 20/06/2024			Variaz. 5gg	Var. 1 gen.
0,1446 ^SEK	-3,60%		-12,26%	-41,10%

30/05	Abliva conclude il dosaggio nello studio intermedio del farmaco per la malattia mitocondriale	MT
30/05	Abliva AB (Publ) annuncia il completamento di 24 settimane di dosaggio nell'ondata 1 dello Studio Falcon di KL1333 nella malattia mitocondriale primaria	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Amended number of shares and votes in Abliva AB (publ)	31/05
Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug	30/05
Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease	30/05
Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease	30/05
Ablivas CEO to BioStock: "We remain on track for the interim analysis early in Q3"	29/05
Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024	23/05
Abliva : Interim Report January - March 2024	23/05
Abliva AB Interim Report January – March 2024	23/05
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2024	23/05
Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024	13/05
Amended number of shares and votes in Abliva AB (publ)	30/04
Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue	25/04
Abliva AB Publishes 2023 Annual Report	24/04
Notice of Annual General Meeting of Abliva AB (publ)	22/04
Abliva publishes rights issue outcome	19/04
BioStock: Abliva's mission to become mitochondrial medicine powerhouse	08/04
Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares	27/03
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)	26/03
BioStock: Abliva's CEO comments on the proposed capital raise	29/02
Abliva AB Year-End Report January – December 2023	23/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Abliva AB

Azioni

ABLI

SE0002575340

Altre lingue

Filtri